Compare Global X Robotics and Artificial Intelligence ETF (BOTZ) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Global X Robotics and Artificial Intelligence ETF vs TransMedics Group Inc — how do they compare? Global X Robotics and Artificial Intelligence ETF trades at $37.86, while TransMedics Group Inc trades at $87.19 (market cap $3.10B). The key difference: Global X Robotics and Artificial Intelligence ETF is trading nearer its 52-week high, TransMedics Group Inc nearer its low. Which is the better fit depends on your goals.
| BOTZ | TMDX | |
|---|---|---|
52-Week High | $41.63 | $150.42 |
52-Week Low | $31.99 | $61.99 |
Market Cap | — | $3.10B |
Sector | — | Technology |
Enterprise Value | — | $3.49B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BOTZ trades at $37.85, up 1.15% today, with a bullish technical signal from moving averages. The ETF's RSI levels suggest overbought conditions, while ADX indicates a strong trend. Recent news highlights its role in robotics and AI investing, with a focus on global tech exposure beyond U.S. markets.
Outlook remains positive due to thematic growth in robotics and AI, supported by institutional interest. Risks include sector volatility and competition from other ETFs. The dividend of $0.02 scheduled for July 2026 adds income appeal, but valuation metrics are unavailable for deeper analysis.
TransMedics Group (TMDX) trades at $87.42, down 1.12% on the day, with a bullish technical outlook from moving averages but bearish oscillators signaling potential overbought conditions. The company reported mixed Q2 2026 results, missing earnings estimates with EPS of $0.44 versus $0.50 expected, while revenue growth remains robust. Recent news highlights an ongoing investigation into fiduciary duties by directors, adding uncertainty.
The stock presents a cautious opportunity with strong analyst support (69% buy ratings) and a consensus price target of $99.57, implying upside, but risks include earnings volatility, margin pressures, and legal scrutiny. Fundamentals show solid profitability with a 22.69% net margin, though valuation multiples like P/E of 23.15 suggest premium pricing relative to historical norms.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Global X Robotics and Artificial Intelligence ETF
The fund invests at least 80% of its total assets in the securities of the underlying index. The underlying index is designed to provide exposure to exchange-listed companies in developed markets that are involved in the development of robotics and/or artificial intelligence. The fund is non-diversified.
Read more on BOTZ →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
